August 11, 2025 Second Quarter 2025 Financial Results & Business Update On Today's Call • Welcome Brendan Strong, SVP, Investor Relations and Corporate Communications • Overview Richard Paulson, President and Chief Executive Officer • Pipeline Update Dr. Reshma Rangwala, Chief Medical Officer and Head of Research • Commercial Highlights Sohanya Cheng, Chief Commercial Officer and Head of Business Development ©2025 KARYOPHARM THERAPEUTICS INC. 2 • Financial Results and Guidance Lori Macomber, Chief Financial ...

Jefferies Global Healthcare Conference June 5, 2025 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's beliefs about the market opportunity and annual peak revenue opportunities for selinexor; expectations with respect to commercialization efforts; the ability of selinexor to treat patients with multiple ...

Jefferies Global Healthcare Conference 3 June 5, 2025 Forward-looking Statements and Other Important Information This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Karyopharm's beliefs about the market opportunity and annual peak revenue opportunities for selinexor; expectations with respect to commercialization efforts; the ability of selinexor to treat patients with multip ...

Financial Performance & Guidance - Q1 2025 XPOVIO净产品收入为2110万美元，受到非典型过期产品退货的影响，减少了约500万美元[86, 87] - 公司预计2025年总收入为140-155百万美元[112] - 公司预计2025年美国XPOVIO净产品收入为115-130百万美元[112] - 公司预计2025年研发和SG&A支出为240-255百万美元，其中包括约2000万美元的非现金股票补偿[112] Myelofibrosis Program - Myelofibrosis的美国峰值年收入机会高达约10亿美元[7, 19] - 在JAKi初治的骨髓纤维化患者中，Selinexor联合Ruxolitinib治疗的SVR35达到79%[28] - 75%的美国医生表示有意采用联合疗法治疗骨髓纤维化[21, 99] Clinical Trials & Pipeline - SENTRY试验的顶线数据预计在2025年末/2026年初公布[7, 59] - XPORT-MF-035试验中，Selinexor单药治疗使脾脏体积缩小率增加了一倍以上，SVR25为67%，SVR35为33%[35, 36] - 完成了评估SPd治疗既往接受过治疗的多发性骨髓瘤患者的3期全球研究（XPORT-MM-031/EMN291）的患者招募，预计在2026年上半年获得顶线数据[78, 79, 81] Commercial Strategy - Selinexor已在超过45个国家获得批准[7, 90] - 现有销售团队已覆盖约80%的社区骨髓纤维化客户[21]